Isradipine (Dynacirc)

A potent antagonist of CALCIUM CHANNELS that is highly selective for VASCULAR SMOOTH MUSCLE. It is effective in the treatment of chronic stable angina pectoris, hypertension, and congestive cardiac failure.

Also Known As:

Dynacirc; Isradipine, (+-)-Isomer; Isradipine, (R)-Isomer; Isradipine, (S)-Isomer; Lomir; PN 200-110; PN 205-033; PN 205-034; PN-200-110; PN-205-033; PN-205-034; PN 205 033; PN 205 034; PN 205033; PN 205034; PN205033; PN205034; 3,5-Pyridinedicarboxylic acid, 4-(4-benzofurazanyl)-1,4-dihydro-2,6-dimethyl-, methyl 1-methylethyl ester

Networked: 501 relevant articles (75 outcomes, 173 trials/studies)

Relationship Network

Drug Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Pyridines: 88
    - Dihydropyridines: 214
      - Isradipine: 501

Experts

1.	Simuni, Tanya: 7 articles (01/2022 - 12/2010)
2.	Oakes, David: 6 articles (01/2022 - 01/2017)
3.	Surmeier, D James: 4 articles (01/2022 - 03/2009)
4.	Striessnig, Jörg: 3 articles (10/2022 - 12/2017)
5.	Ortner, Nadine J: 3 articles (01/2021 - 12/2017)
6.	Anekonda, Thimmappa S: 3 articles (12/2011 - 01/2011)
7.	Quinn, Joseph F: 3 articles (12/2011 - 01/2011)
8.	Ait-Daoud, Nassima: 3 articles (06/2005 - 04/2004)
9.	Johnson, Bankole A: 3 articles (06/2005 - 04/2004)
10.	Roache, John D: 3 articles (06/2005 - 04/2004)

Related Diseases

1.	Hypertension (High Blood Pressure) 02/01/1991 - "In conclusion, these results indicate that isradipine is a novel drug which is highly effective and well tolerated in the treatment of mild to moderate hypertension in this group of patients." 12/01/1991 - "Thus, isradipine proved effective and very well tolerated and may deserve a place as first line treatment for hypertension." 02/15/1990 - "Isradipine was more effective in patients whose clinical hypertension was confirmed by ambulatory BP monitoring (35) than in patients who remained normotensive by ambulatory BP monitoring criteria (41). " 03/01/2002 - "Isradipine is effective in the treatment of arterial hypertension following CABG. " 01/01/1992 - "Thus, our results indicate that isradipine is effective and well tolerated, and may deserve a place as first-line treatment in mild-to-moderate hypertension."
2.	Essential Hypertension 02/01/1991 - "In conclusion, low-dose isradipine MR once daily is an effective first-line treatment in essential hypertension." 01/01/1990 - "When administered alone to 102 patients with essential hypertension stages I and II, isradipine was effective in 59%. " 12/01/1994 - "Based on these observations, isradipine is a well-tolerated, safe and effective agent for long-term BP control in elderly patients with essential hypertension." 10/01/1987 - "The results indicate that isradipine, administered as monotherapy in doses of 2.5 to 10 mg b.i.d., is safe and effective in patients with mild to moderate essential hypertension." 01/01/1992 - "The safety and efficacy of isradipine as well as its long-term effects on renal hemodynamics were evaluated in a study of 17 patients with mild-to-moderate essential hypertension and normal or slightly impaired renal function. "
3.	Atherosclerosis 07/01/1994 - "Experimental and clinical effects of isradipine relevant to atherosclerosis." 01/01/1990 - "The effect of isradipine on atherosclerosis in humans is unknown. " 01/01/1990 - "Isradipine also has antiatherogenic properties in animal models of atherosclerosis. " 01/01/1992 - "Thus, a reasonable hypothesis could be that isradipine not only reduces the level of blood pressure, but also may have a positive effect on the evolution of atherosclerotic plaque in coronary and carotid arteries, thereby leading to prevention of clinical sequelae of atherosclerosis. " 01/01/1992 - "On this basis, a 3-year clinical trial is being carried out in the United States--the Multicenter Isradipine/Diuretic Atherosclerosis Study (MIDAS)--to establish the efficacy of isradipine in inhibiting atherogenesis and retarding the progression of atherosclerosis in carotid arteries of hypertensive patients. "
4.	Tachycardia (Tachyarrhythmias) 12/01/1986 - "Isradipine appears to be effective in lowering blood pressure without reflex tachycardia." 01/01/1993 - "Due to its negative chronotropic properties, the reflex tachycardia was significantly attenuated after isradipine as compared to the other drugs (heart-rate changes: NIF +13 +/- 7%, p < 0.01; ISR +4 +/- 7%, not significant; NIS +20 +/- 10%, p < 0.01; FEL +17 +/- 12%, p < 0.01). " 02/01/1990 - "Sustained monomorphic tachycardias were inducible in five pigs before and in three pigs after isradipine, and no deterioration of the signal-averaged electrocardiogram parameters was found.(ABSTRACT TRUNCATED AT 250 WORDS)" 04/17/1989 - "However, wedge pressure was maintained with isradipine and there was no tachycardia. " 02/01/1991 - "Isradipine lowered systolic and diastolic blood pressure as well as mean arterial pressure in patients with mild-to-moderate essential hypertension without reflex tachycardia or venoconstriction. "
5.	Ischemia 11/01/1995 - "Given before and after ischemia in the mouse, isradipine was also ineffective, whereas SB201823A produced a significant reduction in lesion volume. " 01/01/1992 - "We conclude that isradipine has a beneficial effect on the clinical and electrocardiographic signs of exercise-induced ischemia, leading to a significant improvement of the systolic and diastolic parameters of left ventricular function. " 06/01/1999 - "Use of diffusion-weighted MRI and neurological deficit scores to demonstrate beneficial effects of isradipine in a rat model of focal ischemia." 05/01/1997 - "After normothermic global ischemia, the Bmax of [3H]isradipine binding increased in the left ventricle by 81% (299% +/- 1.7% to 540% +/- 11% fmoles/mg, P < 0.01) and in the right ventricle by 33% (387% +/- 9.9% to 515% +/- 38% fmoles/mg, P < 0.01) compared with control. " 11/01/1995 - "In this fraction, the yield for PN 200-110 binding sites was 4.7 +/- 0.6% in the control condition and 2.8 +/- 0.5% after ischemia (P < 0.05). "

Related Drugs and Biologics

1.	Isradipine (Dynacirc)
2.	Calcium
3.	Diuretics
4.	Antihypertensive Agents (Antihypertensives)
5.	Hydrochlorothiazide (Esidrix)
6.	1,4-dihydropyridine (dihydropyridine)
7.	Amlodipine (Norvasc)
8.	Felodipine (Agon)
9.	spirapril
10.	Nifedipine (Adalat)

Related Therapies and Procedures

1.	Therapeutics
2.	Coronary Artery Bypass (Coronary Artery Bypass Surgery)
3.	Oral Administration
4.	Ligation
5.	Intravenous Infusions